Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment
- 1 October 1999
- Vol. 54 (4) , 694-699
- https://doi.org/10.1016/s0090-4295(99)00316-7
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- A new extra long acting depot preparation of the LHRH analogue Zoladex®. First endocrinological and pharmacokinetic data in patients with advanced prostate cancerPublished by Elsevier ,2003
- TIME TO NORMALIZATION OF SERUM TESTOSTERONE AFTER 3-MONTH LUTEINIZING HORMONE-RELEASING HORMONE AGONIST ADMINISTERED IN THE NEOADJUVANT SETTING: IMPLICATIONS FOR DOSING SCHEDULE AND NEOADJUVANT STUDY CONSIDERATIONJournal of Urology, 1998
- INFLUENCE OF RADICAL PROSTATECTOMY ON SERUM HORMONE LEVELSJournal of Urology, 1998
- Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancerClinical Therapeutics, 1996
- A New Long Acting Formulation of the Luteinizing Hormone-Releasing Hormone Analogue, Goserelin: Results of Studies in Prostate CancerJournal of Urology, 1996
- Randomized Open Labelled Comparative Study of the Efficacy, Safety and Tolerability of Leuprorelin Acetate 1M and 3M Depot in Patients with Advanced Prostatic CancerEuropean Urology, 1996
- The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancerUrology, 1994
- Regression Models and Life-TablesJournal of the Royal Statistical Society Series B: Statistical Methodology, 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958